Methadone treatment has played a critical role in addressing Opioid Use Disorder (OUD) in the United States for more than 50 years. Originally developed through groundbreaking research in the 1960s, methadone is a long-acting medication that reduces opioid cravings and withdrawal symptoms, helping individuals with OUD stabilize and rebuild their lives.
Today, methadone is delivered through federally regulated Opioid Treatment Programs (OTPs), which combine medication with counseling and comprehensive care. This structured, evidence-based approach has been proven to reduce overdose risk, improve treatment retention and support long-term recovery, making OTPs an effective model for treating OUD.
Where Methadone Treatment Began: The 1960s
The history of methadone as an addiction treatment begins at Rockefeller University in New York City. In the early 1960s, heroin addiction was becoming a serious public health crisis in American cities. At the time, addiction was widely seen as a moral failing rather than a medical condition, and effective treatments were nearly nonexistent.
At the same time, the broader medical community was largely unwilling to treat people with opioid use disorder. Addiction was not widely accepted as a medical condition, and many physicians declined to engage in treatment. As a result, methadone treatment developed outside of traditional healthcare settings, laying the groundwork for a separate, highly regulated system of care.
In 1964, Dr. Vincent Dole and Dr. Marie Nyswander, along with researcher Dr. Mary Jeanne Kreek, began groundbreaking clinical studies. Their research challenged the prevailing view of addiction and helped establish that opioid dependence is a chronic, treatable medical condition.
They found that methadone, a long-acting opioid medication, could stabilize brain chemistry by activating opioid receptors in a slow, controlled way. Their research proved that methadone could reduce cravings and curb withdrawal symptoms without producing the intense euphoria associated with short-acting opioids like heroin. With cravings controlled, patients were able to function normally in daily life.
While Dole and Nyswander were leaders in this work, they were part of a broader shift toward medication-based treatment. Their findings helped catalyze the rapid expansion of methadone treatment from research settings into communities across the country.
What Are Opioid Treatment Programs (OTPs)?
As methadone treatment expanded through the late 1960s and early 1970s, demand for treatment grew rapidly, but not always with consistent oversight.
In some early programs, the lack of standardized protocols led to inconsistent dosing practices and instances of diversion, where methadone was used outside of supervised treatment. These challenges underscored a critical lesson: while methadone is highly effective, it must be delivered within a structured, medically supervised system to ensure safety and success.
Federal policymakers chose to limit methadone treatment to specialized clinics rather than integrate it into general medical practice. While this decision reflected evidence supporting comprehensive, structured care, it also reflected ongoing discomfort within mainstream medicine around treating addiction and a desire for heightened control over this patient population.
Over time, the specialized clinics themselves became some of the strongest advocates for modernizing these rules, supporting regulations that preserve safety and accountability while also pushing for more flexible, individualized and patient-centered care.
At the same time, the impact of treatment was clear. The number of patients receiving methadone grew from approximately 9,000 in 1971 to more than 70,000 by 1973, reflecting both urgent need and strong early outcomes.
In 1972, the FDA and DEA established formal regulations requiring that methadone for opioid use disorder be dispensed through federally approved clinics with strict oversight. These clinics became what we now call Opioid Treatment Programs, or OTPs.
OTPs were designed to do more than dispense medication. They provide comprehensive, evidence-based care, including counseling, behavioral therapies and case management, addressing the full scope of patients’ needs. This model helped reduce the risks associated with earlier, less structured approaches while improving treatment outcomes.
A Modern Framework: SAMHSA Takes the Lead
In January 2001, federal regulations shifted oversight of OTPs from the FDA to the Substance Abuse and Mental Health Services Administration (SAMHSA), following recommendations from the Institute of Medicine to modernize care and improve outcomes.
This transition marked a move toward a more patient-centered, outcomes-based model. It also reflected growing recognition that overly rigid regulations could create barriers to care and limit providers’ ability to tailor treatment to individual patient needs. OTPs were required to obtain accreditation from a SAMHSA-approved body, reinforcing standards around quality of care, individualized treatment planning and accountability.
Since then, the OTP system has continued to grow and evolve. Today, more than 1,900 OTPs operate across the country, serving hundreds of thousands of patients each year.
This federal framework continues to evolve in response to the ongoing overdose crisis. In 2018, Congress passed the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act. This landmark piece of legislation increased access to medication-assisted treatment.
In 2025, Congress reauthorized the SUPPORT for Patients and Communities Act and Reauthorization Act extending key federal programs through 2030. The law focuses on enhancing overdose prevention, expanding access to treatment, and strengthening the addiction treatment workforce, including support for state Prescription Drug Monitoring Programs (PDMPs). These efforts reinforce the role of Opioid Treatment Programs within a broader strategy to improve access to evidence-based care while maintaining strong clinical and regulatory standards.
This growth reflects more than increasing need, it highlights the strength and reliability of the OTP model as one of the most effective approaches to treating opioid use disorder.
COVID-19 and a New Era of Flexibility
The COVID-19 pandemic marked an important shift in how OTP care could be delivered. In March 2020, to protect patient exposure to COVID-19 and follow social distancing guidelines, SAMHSA introduced flexibilities such as expanded access to take-home doses and increased use of telehealth.
Many OTP providers had long argued that some federal restrictions were more rigid than necessary and limited patient-centered care. These changes were closely studied, and the findings were clear: increased flexibility did not lead to rises in methadone-related overdose, diversion, or misuse. Instead, they improved access to care and helped patients remain engaged in treatment.
In February 2024, many of these changes were made permanent demonstrating that it is possible to expand access while maintaining the safety and structure that make OTPs effective. A recent SAMHSA report found that 71% of OTPs have implemented at least half of the changes and 93% of OTPs have implemented at least a quarter of the changes. Additionally, data aggregated from four OTP networks representing 382 treatment centers show that:
- 50% of patients come into the clinic for medication once a week or less
- 78% of patients receive at least 3 take-homes a week
- 29% of patients are initiated through telehealth
These permanent changes, alongside ongoing federal efforts such as the SUPPORT Act, reflect a broader policy shift toward expanding access within the existing OTP framework while preserving the structure and accountability that define its effectiveness.
More Than 50 Years of Saving Lives
From a small research effort in New York City to a nationwide system of care, the history of methadone and OTPs is a story of science, structure and sustained impact.
Methadone treatment delivered through OTPs has been shown to:
- Reduce illicit opioid use
- Lower the risk of overdose and death
- Improve treatment retention, one of the strongest predictors of long-term recovery
- Help patients achieve greater stability in their lives
For more than 50 years, OTPs have provided safe, effective and comprehensive care to millions of people. Their success demonstrates a clear truth: when methadone is delivered within a structured, evidence-based system that balances safety, accountability and individualized care, it is one of the most effective treatments for opioid use disorder.
This history is often overlooked in current policy discussions. Efforts to “expand” access by allowing physicians outside of OTPs to treat addiction with methadone assume that these settings can generate the same results. It misses a core component to the success — treatment requires more than a dose of methadone, the best treatment provides a full-service program with counseling, social supports and other wrap around services and safeguards. There is no evidence that methadone treatment outside of an OTP would generate the same high-quality results for people engaged in treatment. In reality, opioid treatment programs emerged in part because mainstream medicine was not meeting the needs of this population.
Understanding that history is critical to ensuring that future policy changes preserve both the safety standards that support effective treatment and the flexibility needed to provide individualized, patient-centered care.
Leave a Reply